UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 82

Sortiert nach

From inflammation to cancer: entering a new frontier in the management of Erdheim–Chester disease

Neuro-oncology (Charlottesville, Va.), 2020-07, Vol.22 (7), p.905-906

Nayak, Lakshmi

2020

Link zum Volltext

Verfügbarkeit prüfen

Introduction of novel agents in the treatment of primary CNS lymphoma

Neuro-oncology (Charlottesville, Va.), 2019-02, Vol.21 (3), p.306-313

2019

Link zum Volltext

Verfügbarkeit prüfen

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

Neuro-oncology (Charlottesville, Va.), 2016-04, Vol.18 (4), p.557-564

2016

Link zum Volltext

Verfügbarkeit prüfen

Medical management of brain tumors and the sequelae of treatment

Neuro-oncology (Charlottesville, Va.), 2015-04, Vol.17 (4), p.488-504

2015

Link zum Volltext

Verfügbarkeit prüfen

INNV-16. COMPARISON OF SURVIVAL OUTCOMES OF RECURRENT GLIOBLASTOMA PATIENTS: A COMPARISON BETWEEN PATIENTS ENROLLED INTO CLINICAL TRIALS AND PATIENTS THAT DID NOT ENROLL INTO TRIALS AT FIRST PROGRESSION

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v159-v160

2023

Link zum Volltext

Verfügbarkeit prüfen

CTIM-36. IMMUNOHISTOCHEMISTRY EVALUATION ON PRE-TREATMENT TUMOR TISSUE PREDICTS TREATMENT RESPONSE TO MN-166 (IBUDILAST) AND TEMOZOLOMIDE COMBINATION THERAPY IN GLIOBLASTOMA PATIENTS

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v70-v71

2023

Link zum Volltext

Verfügbarkeit prüfen

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria

Neuro-oncology (Charlottesville, Va.), 2017-05, Vol.19 (5), p.625-635

2017

Link zum Volltext

Verfügbarkeit prüfen

CTNI-47. DOSE ESCALATION OF ASTX727 IN ADULT PATIENTS WITH RECURRENT/PROGRESSIVE NON-ENHANCING IDH MUTANT GLIOMAS

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v85-v86

2023

Link zum Volltext

Verfügbarkeit prüfen

BIOM-47. PREDICTORS OF SEIZURE AT ONSET USING A FUNCTIONAL VARIANT ANALYSIS OF TARGETED NEXT GENERATION SEQUENCING IN GBM

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii15-vii15

2022

Link zum Volltext

Verfügbarkeit prüfen

CTIM-18. PHASE 2 STUDY OF PD-1 BLOCKADE WITH PEMBROLIZUMAB PLUS RE-IRRADIATION FOR RECURRENT GLIOBLASTOMA (RGBM) (NCT03661723)

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii63-vii64

2022

Link zum Volltext

Verfügbarkeit prüfen

INNV-09. PILOT STUDY OF A SMARTPHONE-BASED SYMPTOM ASSESSMENT (OURBRAINBANK) FOR SUBJECTS WITH GLIOBLASTOMAS

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi139-vi140

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

Neuro-oncology (Charlottesville, Va.), 2015-06, Vol.17 (6), p.862-867

2015

Link zum Volltext

Verfügbarkeit prüfen

RARE-22. CHALLENGES IN MANAGEMENT OF CNS INVOLVEMENT OF CUTANEOUS T-CELL LYMPHOMA

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Supplement_6), p.vi226-vi226

2019

Link zum Volltext

Verfügbarkeit prüfen

CTIM-39. A PHASE 1B STUDY OF PEMBROLIZUMAB, IBRUTINIB AND RITUXIMAB IN RECURRENT/REFRACTORY (RR) PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v71-v72

2023

Link zum Volltext

Verfügbarkeit prüfen

CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM)

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii35-ii35

2020

Link zum Volltext

Verfügbarkeit prüfen

BIOM-30. BLOOD COUNTS THROUGH TREATMENT COURSE IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING CHEMORADIATION

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi17-vi17

2021

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (11), p.1547-1553

2014

Link zum Volltext

Verfügbarkeit prüfen

Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making

Neuro-oncology (Charlottesville, Va.), 2022-07, Vol.24 (7), p.1140-1149

2022

Link zum Volltext

Verfügbarkeit prüfen

CTIM-02. PHASE 2 TRIAL OF PEMBROLIZUMAB FOR PATIENTS WITH BRAIN METASTASES OF DIVERSE HISTOLOGIES

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v60-v61

2023

Link zum Volltext

Verfügbarkeit prüfen

HOUT-28. OFF-LABEL USE OF PD-1 BLOCKADE WITH OR WITHOUT BEVACIZUMAB CONFERS ONLY LIMITED CLINICAL BENEFIT IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi112-vi112

2017

Link zum Volltext

Verfügbarkeit prüfen

CTIM-09. ENRICHED TCR/BCR VDJ REARRANGEMENTS CORRELATE WITH MRI AND SURVIVAL OUTCOMES IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA TREATED WITH CAN-3110

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii61-vii61

2022

Link zum Volltext

Verfügbarkeit prüfen

PATH-15. THE PROGNOSTIC IMPLICATION OF MGMT PROMOTER METHYLATION IN IDH-MUTANT GLIOMAS

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii153-vii153

2022

Link zum Volltext

Verfügbarkeit prüfen

OTHR-08. Pediatric Neurologic Assessment in Neuro-oncology (pNANO) Scale: A tool to assess neurologic function for Response Assessment in Neuro-oncology (RAPNO)

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i148-i148

2022

Link zum Volltext

Verfügbarkeit prüfen

CTIM-37. A PILOT STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSED/REFRACTORY PRIMARY AND SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL AND SCNSL)

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v71-v71

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 82

Suche als RSS-Feed

Aktive Filter

KollektionOxford Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(82)

Publikationsform

Artikel
(82)

Sprache

Englisch
(82)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Clinical Neurology
(18)
Life Sciences & Biomedicine
(18)
Neurosciences & Neurology
(18)
Science & Technology
(18)
Oncology
(16)
Abstracts
(13)
Humans
(13)
Clinical Investigations
(10)
Female
(8)
Male
(8)
Middle Aged
(8)
Abstracts From The 20th Annual Scientific Meeting Of The Society For Neuro-Oncology
(7)
Adult
(7)
Aged
(6)
Follow-Up Studies
(5)
Glioblastoma
(5)
Neoplasm Recurrence, Local - Pathology
(5)
Brain Neoplasms - Drug Therapy
(4)
Cancer Research
(4)
Clinical Trials: Immunologic
(4)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Oxford University Press Journals Current
(82)
Oxford Journals 2020 Medicine
(82)
RCN full-text journals@Ovid
(82)
EZB Electronic Journals Library
(81)
IngentaConnect
(14)
IngentaConnect Journals
(8)
NUS Single-Journal Subscriptions
(1)

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

From inflammation to cancer: entering a new frontier in the management of Erdheim–Chester disease

Introduction of novel agents in the treatment of primary CNS lymphoma

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

Medical management of brain tumors and the sequelae of treatment

INNV-16. COMPARISON OF SURVIVAL OUTCOMES OF RECURRENT GLIOBLASTOMA PATIENTS: A COMPARISON BETWEEN PATIENTS ENROLLED INTO CLINICAL TRIALS AND PATIENTS THAT DID NOT ENROLL INTO TRIALS AT FIRST PROGRESSION

CTIM-36. IMMUNOHISTOCHEMISTRY EVALUATION ON PRE-TREATMENT TUMOR TISSUE PREDICTS TREATMENT RESPONSE TO MN-166 (IBUDILAST) AND TEMOZOLOMIDE COMBINATION THERAPY IN GLIOBLASTOMA PATIENTS

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria

Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results

CTNI-47. DOSE ESCALATION OF ASTX727 IN ADULT PATIENTS WITH RECURRENT/PROGRESSIVE NON-ENHANCING IDH MUTANT GLIOMAS

BIOM-47. PREDICTORS OF SEIZURE AT ONSET USING A FUNCTIONAL VARIANT ANALYSIS OF TARGETED NEXT GENERATION SEQUENCING IN GBM

CTIM-18. PHASE 2 STUDY OF PD-1 BLOCKADE WITH PEMBROLIZUMAB PLUS RE-IRRADIATION FOR RECURRENT GLIOBLASTOMA (RGBM) (NCT03661723)

INNV-09. PILOT STUDY OF A SMARTPHONE-BASED SYMPTOM ASSESSMENT (OURBRAINBANK) FOR SUBJECTS WITH GLIOBLASTOMAS

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

RARE-22. CHALLENGES IN MANAGEMENT OF CNS INVOLVEMENT OF CUTANEOUS T-CELL LYMPHOMA

CTIM-39. A PHASE 1B STUDY OF PEMBROLIZUMAB, IBRUTINIB AND RITUXIMAB IN RECURRENT/REFRACTORY (RR) PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)

CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM)

BIOM-30. BLOOD COUNTS THROUGH TREATMENT COURSE IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING CHEMORADIATION

Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma

Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making

CTIM-02. PHASE 2 TRIAL OF PEMBROLIZUMAB FOR PATIENTS WITH BRAIN METASTASES OF DIVERSE HISTOLOGIES

HOUT-28. OFF-LABEL USE OF PD-1 BLOCKADE WITH OR WITHOUT BEVACIZUMAB CONFERS ONLY LIMITED CLINICAL BENEFIT IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA

CTIM-09. ENRICHED TCR/BCR VDJ REARRANGEMENTS CORRELATE WITH MRI AND SURVIVAL OUTCOMES IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA TREATED WITH CAN-3110

PATH-15. THE PROGNOSTIC IMPLICATION OF MGMT PROMOTER METHYLATION IN IDH-MUTANT GLIOMAS

OTHR-08. Pediatric Neurologic Assessment in Neuro-oncology (pNANO) Scale: A tool to assess neurologic function for Response Assessment in Neuro-oncology (RAPNO)

CTIM-37. A PILOT STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSED/REFRACTORY PRIMARY AND SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL AND SCNSL)

Aktive Filter

Suchergebnisse filtern